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Hepatocellular carcinoma (HCC) is developed by multiple steps accompanying progressive 
alterations of gene expression, which leads to increased cell proliferation and malignancy. 
Although environmental factors and intracellular signaling pathways that are critical for HCC 
progression have been identified, gene expression changes and the related genetic factors 
contributing to HCC pathogenesis are still insufficiently understood. In this study, we identify a 
transcriptional repressor Capicua/CIC as a suppressor of HCC progression and a potential 
therapeutic target. Expression of CIC is posttranscriptionally reduced in HCC cells. CIC levels 
are correlated with survival rates in patients with HCC. CIC overexpression suppresses HCC cell 
proliferation and invasion, whereas loss of CIC exerts opposite effects in vivo as well as in vitro. 
The levels of PEA3 group genes, the best-known CIC target genes, are correlated with lethality 
in patients with HCC. Among the PEA3 group genes, ETV4 is the most significantly upregulated 
gene in CIC-deficient HCC cells, consequently promoting HCC progression. Furthermore, ETV4 
induces expression of MMP1, the MMP gene highly relevant to HCC progression, in HCC cells, 
and knockdown of MMP1 completely blocks the CIC deficiency-induced HCC cell proliferation 
and invasion. Conclusion: Our study demonstrates that the CIC-ETV4-MMP1 axis is a novel 
regulatory module controlling HCC progression. 
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Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide 
and the fifth most common malignancy, especially in East Asia and South Africa (1, 2). In most 
cases, human HCC is driven by chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) 
infections, alcoholic abuse, non-alcoholic fatty liver disease, autoimmune hepatitis, diabetes 
mellitus, and several metabolic diseases (3). 
Among multiple therapeutic strategies to overcome HCC, liver resection is still the best 
therapeutic strategy to treat HCC with a 5-year survival rate in approximately 70% (3). Another 
option of HCC treatment is the orthotopic liver transplantation, which has the lowest risk of 
tumor recurrence but is applied to very few patients. Radiofrequency ablation (RFA) and trans-
arterial chemoembolization (TACE) are other therapeutic strategies but have marginal effects. 
Because of these limitations of HCC treatment, many studies are focused on finding molecular 
therapies for HCC. Sorafenib, a related multikinase inhibitor, is currently the only drug approved 
for advanced HCC management. Despite sorafenib treatment, overall survival is increased by 
only 37%, with several major side effects including acne-like rash, diarrhea, fatigue, and 
hypertension (4).  
In search for a better understanding and efficacious treatment in HCC, many cancer drivers and 
molecular therapies have been reported (5). Some studies have explored HCC genomic 
alterations and identified frequently mutated genes, including TERT promoter, TP53, and 
CTNNB1 (β-catenin) (6, 7). In addition, chromosomal amplifications (1q, 6p, 8q, 11q, 17q, and 
20q) and deletions (4q, 8p, 13q, 16q, and 17p) that affect important oncogenes and tumor 
suppressors have been identified in samples from patients with HCC (8). Moreover, several 
Page 4 of 69
Hepatology
Hepatology





signaling pathways are investigated to be targeted by novel therapies for HCC including RAS, 
TGF-β, FGF-19/FGFR-4, and MET signaling pathways (9). Importantly, RAS signaling is 
related to cell survival and proliferation and is activated in more than 50% of HCCs (10, 11) . 
Although HCC progression is considered as a multistep and a long-term progressive process, the 
precise molecular mechanism of HCC pathogenesis remains largely unknown (12). 
Capicua/CIC is a transcriptional repressor that is highly conserved from C. elegans to humans 
(13). There are two main isoforms of CIC, the short (CIC-S) and long (CIC-L) form, which 
differ in their amino-terminal portions. CIC has two highly conserved domains: a DNA-binding 
high mobility group (HMG) box domain and a carboxy-terminal motif (C1) (13). CIC 
preferentially recognizes T(G/C)AATG(G/A)A sequences through the HMG-box and C1 
domains to repress expression of its target genes in Drosophila and mammals (14-16). CIC 
activity can be regulated by receptor tyrosine kinase (RTK) signaling pathways in Drosophila 
and mammals (17-19). Activation of RTK-MAPK pathways phosphorylates CIC, resulting in 
degradation and/or cytoplasmic localization of CIC (20, 21). 
Cic was firstly identified in a screen for mutations affecting tissue patterning in Drosophila 
embryo (17). In Drosophila, several studies revealed that Cic regulates not only anteroposterior 
and dorsoventral body patterning, but also intestinal stem cell proliferation (22), wing  
development (23), and other processes in development (24).  
In mammals, CIC has been implicated in pathogenesis of spinocerebellar ataxia type-1 
neurodegenerative disease (25), as well as regulation of essential processes such as lung 
alveolarization (26), liver homeostasis (27), learning and memory (28), and follicular helper T 
cell differentiation (29). CIC has also been studied in several cancer contexts, and its mutations 
were found in soft tissue, brain, lung, gastric, prostate, and breast cancers (14, 21, 30-32). 
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Furthermore, CIC directly suppresses expression of PEA3 group genes (ETV1, ETV4, and ETV5), 
which are known to be frequently overexpressed in many cancers and have tumor-promoting 
functions (14, 30, 33, 34). 
Although increasing evidences have indicated that CIC functions as a tumor suppressor in 
various cancers (19, 21, 35, 36), no studies have examined its clinicopathologic significance and 
molecular functions in HCC. In this study, we present the first evidence that decreased level of 
CIC is associated with HCC progression and indicates poor prognosis. Both in vitro and in vivo 
assays demonstrate that CIC has a tumor suppressive function in the progression of HCC. 
Molecular studies reveal that CIC regulates ETV4 expression in HCC cells and that MMP1 acts 
as a key downstream target of the CIC-ETV4 axis in HCC context. Therefore, our findings 
suggest that CIC-ETV4-MMP1 regulatory axis might have a critical role in HCC progression. 
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Tissue microarray and immunohistochemistry 
Two liver cancer tissue microarrays with liver tumors and adjacent normal liver tissues (LV1221 
and LV6161) were purchased from Biomax (MD, USA). Formalin-fixed paraffin-embedded 
specimens were de-paraffinized and stained with rabbit polycolonal anti-CIC antibody. Each 
sample stained with anti-CIC antibody was scored as negative (-), weak (+), moderate (++), or 
strong (+++) according to the staining intensity. These scores were determined independently by 
two pathologists. The scoring by the pathologists was done in a blinded manner. 
 
Induction of HCC in mice 
To induce HCC, diethylnitrosamine (DEN, Sigma-Aldrich, MO, USA) was injected 
intraperitoneally (i.p.) into 2-week-old male mice (5 µg/g). For tumor formation analysis, mice 
were sacrificed to prepare liver tissues at 8 months after DEN treatment. Externally visible 
tumors (>1 mm) on liver were counted and measured. Livers were micro-dissected into tumor 
and non-tumor and stored at −80°C until analyzed by qRT-PCR. 
Lung metastasis and survival were analyzed at 15 months after DEN treatment. The survival of 
the mice was recorded weekly. After 15 months, the mice were sacrificed, and their lungs were 
dissected, paraffin-embedded, and used for H&E staining. Serial sections of entire lung tissues 
were conducted. Four sections per each lung tissue were chosen for H&E staining. Total number 
of metastasized tumor lesions was counted from the H&E-stained sections and used for 
calculation of the average number of tumor foci in a lung tissue per each genotype. 
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Other assays used in this study are described in the Supporting Information. 
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Inverse correlation between CIC protein levels and HCC severity 
Since the role of CIC in HCC development and progression has not yet been determined, we 
analyzed The Cancer Genome Atlas (TCGA) data sets for patients with HCC (Table S1) in order 
to gain insight on the relevance between CIC and HCC pathogenesis. CIC mRNA levels were 
not downregulated, but rather increased in HCC tissue samples compared with normal liver 
tissues (Fig. 1A). However, the survival rate was significantly decreased in HCC patients with 
low levels of CIC (the lower 20%, n=74) compared with those with high levels of CIC (the upper 
20%, n=74) (Fig. 1B and Table S2). Previous studies have demonstrated that activation of EGFR 
and its downstream signaling molecules, which promotes tumorigenesis and cancer metastasis, 
inactivates CIC via either degradation or cytoplasmic translocation (20, 21). Moreover, we have 
shown that CIC protein levels were dramatically decreased in prostatic adenocarcinoma (35). 
Thus, we examined CIC protein levels in normal liver and HCC tissues on tissue microarrays by 
immunohistochemistry using anti-CIC antibody. Reduced expression of CIC was more 
frequently observed in HCC samples than in normal liver tissues (Fig. 1C). To directly address 
whether CIC expression decreases in HCC tissues at protein level, but not at mRNA level, we 
examined expression profiles of both CIC protein and CIC mRNA in the same tissue samples of 
normal liver and HCC of different pathological stages (Table S3). Most HCC tissues showed 
reduction in CIC protein levels compared with normal liver tissues, whereas CIC mRNA level 
was not correlated with CIC protein level in each tissue sample (Fig. 1D), suggesting the 
posttranscriptional regulation of CIC expression in HCC cells. Taken together, these data 
indicate the association of CIC levels with HCC progression. 
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CIC suppresses HCC progression  
To test whether CIC has a suppressive function in HCC progression, we examined the effect of 
CIC overexpression on HCC cell growth and invasion. We chose SK-HEP-1 and MHCC-97H 
cells, which are highly metastatic and aggressive HCC cell lines (37, 38), for the experiments, 
because they express relatively low levels of CIC compared with other HCC cell lines (Fig. S1). 
Forced expression of either CIC-S or CIC-L suppressed cell proliferation, invasion, and 
migration in both cell lines (Figs. 2A-D). Then, we tested whether suppression of CIC expression 
has the opposite effects. HCC cells that stably express shRNA against CIC (shCIC) had 
increased proliferation rate and invasive and migratory activity compared with control HCC cells 
(Figs. 2E-H). CRISPR-Cas9-mediated knockout of CIC also promoted HCC cell proliferation 
and invasion (Fig. S2). We confirmed these results in vivo using xenograft mouse models. 
Control and shCIC-expressing SK-HEP-1 or MHCC-97H cells were subcutaneously injected into 
either posterior flank of the same nude mice, respectively, and tumor volume was measured 
every week. The CIC-deficient HCC cells grew more rapidly and formed larger tumor mass than 
the control cells (Fig. 3A). To compare metastatic activity between control and CIC-deficient 
HCC cells, the cells were intravenously injected into nude mice followed by quantification of 
GFP signal, which is expressed from shRNA-expressing lentiviral vectors (pGIPZ), in lung 
tissues. The CIC-deficient HCC cells had higher degree and frequency of metastasis to lung than 
control cells (Figs. 3B, C). Taken together, these findings indicate that CIC functions as a 
negative regulator in HCC progression.  
 
Increased lung metastasis and lethality in Cic-deficient mice treated with DEN 
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To better understand in vivo effect of CIC deficiency on HCC progression, we generated mice 
with a specific deletion of Cic alleles in hepatocytes (Cic
f/f
;Alb-Cre, Cic LKO) (Fig. 4A) and 
induced liver cancer in these mice by treatment with diethylnitrosamine (DEN). WT (Cic
f/f
) and 
Cic LKO mice were intraperitoneally injected with DEN at 2 weeks of age and subjected to 
analyses of tumorigenesis, lung metastasis, and viability (Fig. 4B). Tumor formation on liver 
tissues was comparable between WT and Cic LKO mice at 8 months of age (Fig. 4C). However, 
lung metastasis was substantially increased in Cic LKO mice at 15 months of age (Fig. 4D). 
Moreover, about 30% of Cic LKO mice died after 1 year of age, whereas none of WT mice did 
(Fig. 4E). These results demonstrate that reduction in CIC expression can critically contribute to 
promotion of HCC progression, which is consistent with the finding that the survival rate was 
decreased in the HCC patients with low levels of CIC (Fig. 1B). 
 
ETV4 is a critical CIC target that promotes HCC progression 
Many studies have shown that PEA3 group genes, which include ETV1, ETV4, and ETV5, are 
direct target genes of CIC (14, 19, 25, 26) and that overexpression of these genes promotes 
proliferation and invasion of various types of cancer cell (33). However, the role of PEA3 group 
transcription factors in HCC progression has not yet been comprehensively understood. 
Therefore, we analyzed expression profiles of PEA3 group genes and association of these gene 
expression levels with lethality in patients with HCC using the TCGA database (Tables S1 and 
S4). Among three genes, only ETV4 levels were increased in all stages of HCC cells with 
statistical significance compared with normal liver cells (Fig. 5A). On the other hand, overall 
survival rates of HCC patients were inversely correlated with the levels of all PEA3 group genes 
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(Fig. 5B), suggesting that PEA3 group transcription factors might also function as a tumor 
promoter in the context of HCC progression. 
Next, we examined whether CIC regulates expression of PEA3 group genes in HCC cells. The 
levels of PEA3 group genes in control and shCIC-expressing HCC cells were determined by 
qRT-PCR analysis (Fig. 5C). Among three genes, ETV4 levels were most significantly 
upregulated in three different HCC cell lines with CIC RNAi (Fig. 5C). Knockdown of CIC did 
not increase levels of PEA3 group genes in HepG2 cells (Fig. 5C), suggesting that CIC 
differentially regulates its target gene expression in a cell-type dependent manner, which is 
consistent with previous findings (27, 35, 39). Furthermore, the upregulation of ETV4 expression 
in CIC knockdown HCC cells was confirmed at protein level (Fig. 5D). Increases in Etv4 levels 
were also most apparent in both normal liver and DEN-induced tumor tissues from Cic LKO 
mice compared with those in Etv1 and Etv5 (Figs. 5E-G). Overall, these data suggest that, among 
PEA3 group genes, ETV4 is a major target gene of CIC in hepatic cells. 
Given that ETV4 had the highest relevance to HCC progression (Figs. 5A, B) and that ETV4 
expression was most significantly regulated by CIC in HCC cells (Fig. 5C), we focused on the 
role of ETV4 in HCC progression. We first tested whether ETV4 has HCC-promoting activity. 
Overexpression of ETV4 indeed increased cell proliferation, invasion, and migration in HCC 
cells (Figs. 6A-D and S3). We next examined whether the increased cell proliferation, invasion, 
and migration in CIC-deficient HCC cells were due to derepression of ETV4. Knockdown of 
ETV4 completely blocked the CIC deficiency-mediated promotion of HCC progression (Fig. 6E-
H), demonstrating that ETV4 is a key target gene of CIC in regulation of HCC progression.  
 
Regulation of MMP1 expression by the CIC-ETV4 axis in HCC cells 
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 Matrix metalloproteinases (MMPs) promote cancer progression through various ways including 
destruction of extracellular matrix, activation of growth factors, suppression of apoptosis, and 
induction of angiogenesis (40). Therefore, MMPs are the principle mediators of cancer 
progression and frequently used as biomarkers for various types of cancer. There are 23 
members of MMP in humans. Previous studies revealed that PEA3 group transcription factors 
activate expression of various MMP genes and that most MMP genes harbor ETS binding 
elements in their promoters (26, 41). To gain insight on which MMPs are critically involved in 
HCC progression, we analyzed the relevance of each MMP to HCC progression using the TCGA 
database (Tables S1 and S5), as we did for CIC and PEA3 group genes. Among 23 MMP genes, 
levels of MMP1, MMP9, MMP10, MMP11, MMP12, and MMP14 were significantly higher in 
HCC tissues than in normal liver tissues (Figs. 7A and S4). Analysis of survival rates revealed 
that levels of MMP1, MMP7, MMP10, MMP12, MMP16, and MMP26 were inversely correlated 
with survival rates of HCC patients with statistical significance (Figs. 7B and S5). Thus, these 
analyses identified MMP1, MMP10, and MMP12 as MMP genes strongly associated with 
promotion of HCC progression.  
  Next, we investigated which of the selected MMP genes are regulated by the CIC-ETV4 axis in 
HCC cells. Among MMP1, MMP10, and MMP12, only MMP1 expression was significantly 
induced by ETV4 overexpression in both SK-HEP-1 and MHCC-97H HCC cell lines (Fig. 7C). 
We confirmed that ETV4 enhances MMP1 promoter activity by luciferase assay using MMP1 
promoter-containing reporter construct (Fig. 7D). We further examined regulation of MMP1 
expression by CIC in HCC cells. Knockdown of CIC significantly upregulated levels of MMP1, 
but neither MMP10 nor MMP12, in SK-HEP-1 and MHCC-97H HCC cell lines (Fig. 7E). 
Consistent with this result, overexpression of CIC downregulated MMP1 expression (Fig. S6). 
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On the other hand, expression of MMP13, which belongs to the interstitial collagenase family as 
MMP1 does and shares high amino acid identity (86%) with MMP1 (42), was not significantly 
affected by either ETV4 overexpression or CIC RNAi in HCC cells (Fig. S7), suggesting that the 
CIC-ETV4 axis might selectively regulate expression of MMP1 rather than all members of the 
MMP subfamily with similar biochemical and pathological properties. The levels of Mmp1a, a 
mouse homolog of human MMP1, were also upregulated in liver tumors from 15-month-old Cic 
LKO mice treated with DEN compared with those from WT controls, while the levels of other 
Mmp genes including Mmp2, Mmp9, and Mmp12, which have been implicated in the promotion 
of HCC progression (43, 44), were comparable (Fig. S8). Overall, these results suggest that 
MMP1 might be a key effector MMP protein that functions at the downstream of the CIC-ETV4 
axis in the context of HCC progression. 
To directly address whether the increased expression of MMP1 in CIC-deficient HCC cells was 
due to derepression of ETV4, we examined levels of MMP1 in control and shCIC-expressing 
HCC cells treated with either control siRNA or siRNA against ETV4. Knockdown of ETV4 
certainly restored MMP1 expression to the normal level in CIC-deficient HCC cells (Fig. 7F). 
Taken together, these data suggest that MMP1 expression can be regulated by the CIC-ETV4 
axis in the process of HCC progression. 
 
CIC deficiency promotes HCC progression via MMP1 overexpression  
 Since we identified MMP1 as a critical downstream target gene of the CIC-ETV4 axis in HCC 
cells, we finally determined whether the induction of MMP1 expression contributed to the 
enhanced cancer progression in CIC-deficient HCC cells. We transfected control and shCIC-
expressing HCC cells with either control siRNA or two different siRNAs against MMP1 and 
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examined cell proliferation, invasion, and migration. Knockdown of MMP1 completely 
suppressed the increased cell proliferation and invasive and migratory activity in shCIC-
expressing HCC cells (Figs. 8A-D), demonstrating that the increased expression of MMP1 
indeed critically contributed to the CIC deficiency-mediated promotion of HCC progression. 
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In this study, we demonstrated for the first time that CIC could function as a negative regulator 
of HCC progression via control of ETV4-MMP1 axis (Fig. 8E). Overexpression of CIC 
suppressed HCC cell proliferation and invasion, whereas CIC deficiency promoted HCC 
progression in vivo as well as in vitro. We found a discrepancy between CIC-deficient HCC cells 
and DEN-induced HCC in liver-specific Cic null mice; CIC-deficient HCC cells had increased 
proliferation and invasive activity, while DEN-treated Cic-deficient mice exhibited the enhanced 
lung metastasis, but not tumor formation in livers. This finding implies that loss of CIC might 
not be enough to facilitate the onset of HCC, but nevertheless could contribute to the promotion 
of HCC progression once HCC has occurred. 
 Analyses of the TCGA database and tissue samples from patients with HCC revealed that CIC 
expression is reduced in HCC cells at protein level, but not at mRNA level. These results suggest 
that HCC-promoting factors and/or signaling pathways might downregulate CIC expression in 
HCC cells at posttranscriptional level. It is well known that activation of RTK signaling 
suppresses CIC activity via degradation or cytoplasmic translocation of CIC in Drosophila and 
mammals (13, 20, 21, 25). In this process, ERK, a downstream effector kinase of RTK signaling 
pathways, plays a pivotal role. ERK can interact with CIC (45) and the inhibition of ERK rescues 
CIC activity in the context of EGFR activation (21). These findings suggest that activation of 
ERK and its upstream signaling cascades might be involved in downregulation of CIC protein 
levels. Many studies have demonstrated that RAS/RAF/MEK/ERK signaling pathway is 
associated with HCC pathogenesis (46, 47). Levels of total or phosphorylated ERK are often 
higher in HCC cells than in normal liver cells (48, 49). Moreover, it was reported that ERK is 
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mainly found in the nucleus of HCC cells (46). Therefore, it would be conceivable that the 
decrease in CIC levels in HCC cells was due to the enhanced ERK activity (Fig. 8E).  
 Our study demonstrated the significant relevance of MMP1 to HCC progression. In the context 
of HCC, functional significance of other MMPs, such as MMP2, MMP9, and MMP12, have 
been more appreciated than that of MMP1 (43, 44). However, our comprehensive analyses for 
MMP genes in HCC patients using the TCGA datasets indicated that MMP1 is more significantly 
associated with HCC pathogenesis than other MMPs previously recognized to promote HCC 
progression. The in vitro experiments using HCC cell lines showed that MMP1 deficiency is 
sufficient to suppress HCC cell growth and invasion, underlying the critical role of MMP1 in 
HCC progression. We also provided several evidences that MMP1 is a critical downstream target 
of the CIC-ETV4 axis that contributes to the CIC deficiency-mediated promotion of HCC 
progression. MMP1 expression is under the control of ETV4 and knockdown of MMP1 
completely blocks the increased cell proliferation and invasion in CIC-deficient HCC cells. 
Nevertheless, it cannot be ruled out that other MMPs could also contribute to the enhanced cell 
proliferation and invasion in CIC-deficient HCC cells, because most MMP genes have ETS 
binding elements in their promoters (26). To better understand the molecular mechanism 
underlying the CIC deficiency-mediated promotion of HCC progression, genome-wide 
identification of target genes of CIC as well as ETV4 and studies on their roles in HCC 
pathogenesis need to be followed. 
 This study suggests CIC-ETV4-MMP1axis as a novel genetic module that controls HCC 
progression. Patients with HCC have a poor survival rate mainly due to late diagnosis (50). 
Therefore, it is very important to identify genetic alterations that can predict HCC development 
and progression as early as possible. In this regard, our findings provide novel candidate 
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molecules that might be potentially developed as diagnostic markers as well as therapeutic 
targets for HCC. 
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Figure 1. Decreased CIC protein levels in HCC cells and its correlation with poor survival 
rates in HCC patients. A. Analysis of TCGA database for expression levels of CIC mRNA in 
normal liver (NL) and HCC samples of four different clinicopathologic stages (I, II, III, and IV). 
The numbers in parentheses mean the number of subjects in each group. ***P < 0.001. B. 
Kaplan-Meier analysis of overall survival for HCC patients with high (the upper 20%) or low 
(the lower 20%) CIC expression (74 patients per each subgroup). *P < 0.05. C. Analysis of CIC 
protein levels in normal liver (n=33) and HCC (n=554) tissues using tissue microarrays. 
Immunohistochemical staining of CIC was conducted. Representative immunohistochemistry 
images showing four different expression levels of CIC in normal liver and HCC tissues were 
presented in the left panel. Scale bars indicate 100 µm. The right panel shows the proportion of 
tissue samples with different CIC expression scores. D. Western blot and qRT-PCR analyses of 
CIC expression profiles in normal liver (NL) and HCC samples.  
 
Figure 2. CIC suppresses cell proliferation, migration, and invasion in HCC cells. A. 
Western blot analysis for ectopic expression of CIC-S and CIC-L in HCC cells (SK-HEP-1 and 
MHCC-97H). B. Cell growth assay of control and CIC-overexpressing HCC cells. C. Matrigel 
invasion assay of control and CIC-overexpressing HCC cells. The bottom panel is a bar graph for 
quantification of cell invasiveness. D. Transwell migration assay of control and CIC-
overexpressing HCC cells. The bottom panel is a bar graph for quantification of cell migration. 
E. Western blot analysis showing knockdown efficiency of shCIC in HCC cells. shNC is for a 
negative control shRNA. F. Cell growth assay of control and shCIC-expressing HCC cells. G. 
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Matrigel invasion assay of control and shCIC-expressing HCC cells. The right panel is a bar 
graph for quantification of cell invasiveness. H. Transwell migration assay of control and shCIC-
expressing HCC cells. The right panel is a bar graph for quantification of cell migration. Three 
independent experiments were performed. All error bars show s.e.m. *P < 0.05, **P < 0.01, and 
***P < 0.001.  
 
Figure 3. CIC deficiency promotes tumor growth and metastasis in vivo. A. In vivo 
subcutaneous tumor growth curves of SK-HEP-1 and MHCC-97H cells with shNC- or shCIC-
lentiviral infection. n=12 per each group. The middle panel is a representative image of xenograft 
tumors dissected from the mice after the last measurement of tumor size. The right panel is a 
graph for average weights of the dissected tumors. B. In vivo imaging of lung tissues into which 
intravenously-injected control or shCIC-expressing SK-HEP-1 and MHCC-97H cells 
metastasized. GFP signals expressed in the injected cells are shown as dot plots. The right panel 
is a bar graph for quantification of GFP signals. n=10 per each group. All error bars show s.e.m. 
*P < 0.05 and **P < 0.01. C. A bar graph for the incidence (black area) of lung metastasis in 
each group of the nude mice. 
 
Figure 4. Enhanced lung metastasis in liver-specific Cic null mice treated with DEN. A. 
Western blot images of CIC and β-actin (loading control) in liver and lung tissues of wild-type 
(WT) and liver-specific Cic null (Cic LKO) mice. B. Experimental scheme for analysis of 
tumorigenesis and lung metastasis of HCC in mice treated with diethylnitrosamine (DEN). C. 
Representative images of tumor-bearing livers from 8-month-old WT and Cic LKO mice treated 
with DEN. Arrows indicate tumor foci. The right panel is a bar graph for the average numbers of 
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tumor foci on liver tissues of the DEN-treated WT and Cic LKO mice at 8 months of age. n=6 
per each group. D. Representative images of H&E-stained lung tissues of DEN-treated WT and 
Cic LKO mice at 15 months of age. The right panel is a bar graph for the average numbers of 
tumor lesions in randomly selected lung tissue sections. Numbers of WT and Cic LKO mice used 
for this analysis are 10 and 8, respectively. E. Kaplan–Meier survival curve of the DEN-treated 
WT (n=11) and Cic LKO mice (n=11). All error bars show s.e.m. *P < 0.05. 
 
Figure 5. ETV4 is a major CIC target with the most significant relevance to HCC among 
PEA3 group genes. A. Analysis of TCGA database for expression levels of ETV1, ETV4, and 
ETV5 in normal liver (NL) and HCC samples of four different clinicopathologic stages (I, II, III, 
and IV). The numbers in parentheses mean the number of subjects in each group. B. Kaplan-
Meier analysis of overall survival for HCC patients with high or low expression of PEA3 group 
genes (74 patients per each subgroup). C. qRT-PCR analysis of PEA3 group gene expression 
levels in control and CIC knockdown HCC cells. Experiments were performed more than three 
times, independently. D. Western blot analysis for levels of ETV4 in control and CIC 
knockdown HCC cells. E. qRT-PCR analysis for levels of Cic, Etv1, Etv4, and Etv5 in livers of 
7-week-old WT and Cic LKO mice. n=6 per each genotype. F and G. qRT-PCR analysis for 
levels of Cic, Etv1, Etv4, and Etv5 in liver tumors harvested from the DEN-treated WT and Cic 
LKO mice at 8 months of age (F) and at 15 months of age (G). n=5 per each genotype. All error 
bars show s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001.  
 
Figure 6. CIC deficiency-mediated promotion of HCC progression is due to derepression of 
ETV4. A. Western blot analysis showing ectopic expression of ETV4 in SK-HEP-1 and MHCC-
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97H cells. B-D. Cell growth assay (B), matrigel invasion assay (C), and transwell migration 
assay (D) of control and ETV4-overexpressing HCC cells. E. qRT-PCR analysis for ETV4 
mRNA levels in control and CIC knockdown HCC cells transfected with either control or ETV4 
siRNA. NN: control HCC cells transfected with control siRNA, N4: control HCC cells 
transfected with ETV4 siRNA (siETV4), CN: CIC knockdown HCC cells transfected with 
control siRNA, and C4: CIC knockdown HCC cells transfected with siETV4. F-H. Cell growth 
assay (F), matrigel invasion assay (G), and transwell migration assay (H) of control and CIC 
knockdown HCC cells treated with either control or ETV4 siRNA. Three independent 
experiments were performed. All error bars show s.e.m. *P < 0.05, **P < 0.01, and ***P < 
0.001.  
 
Figure 7. MMP1 expression is regulated by the CIC-ETV4 axis. A. Analysis of TCGA 
database for expression levels of MMP1 in normal liver (NL) and HCC samples of four different 
clinicopathologic stages (I, II, III, and IV). The numbers in parentheses mean the number of 
subjects in each group. B. Kaplan-Meier analysis of overall survival for HCC patients with high 
or low MMP1 expression (74 patients per each subgroup). C. qRT-PCR analysis for levels of 
MMP1, MMP10, and MMP12 in control and ETV4-overexpressing HCC cells (SK-HEP-1 and 
MHCC-97H). D. Dual luciferase assay for regulation of MMP1 promoter activity by ETV4. The 
left panel is a schematic illustration for the luciferase reporter construct harboring MMP1 
promoter region (-663/+1), in which there are two putative ETV4 binding sites (-323/-319 and -
155/-149). The right panel is a bar graph for relative luciferase activity in the presence or 
absence of ETV4 overexpression. E. qRT-PCR analysis for levels of MMP1, MMP10, and 
MMP12 in control and CIC knockdown HCC cells. F. qRT-PCR analysis for MMP1 levels in 
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control and CIC knockdown HCC cells treated with either control or ETV4 siRNA. NN: control 
HCC cells transfected with control siRNA, N4: control HCC cells transfected with siETV4, CN: 
CIC knockdown HCC cells transfected with control siRNA, and C4: CIC knockdown HCC cells 
transfected with siETV4. Three independent experiments were performed. All error bars show 
s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001.  
 
Figure 8. Upregulation of MMP1 expression contributes to the increased cell proliferation 
and invasion in CIC knockdown HCC cells. A. qRT-PCR analysis for MMP1 levels in control 
and CIC knockdown HCC cells treated with either control or MMP1 siRNAs. NN: control HCC 
cells transfected with control siRNA, N1-1: control HCC cells transfected with MMP1 siRNA-1 
(siMMP1-1), N1-2: control HCC cells transfected with MMP1 siRNA-2 (siMMP1-2), CN: CIC 
knockdown HCC cells transfected with control siRNA, C1-1: CIC knockdown HCC cells 
transfected with siMMP1-1, and C1-2: CIC knockdown HCC cells transfected with siMMP1-2. 
B-D. Cell proliferation assay (B), matrigel invasion assay (C), and transwell migration assay (D) 
of control and CIC knockdown HCC cells treated with either control or MMP1 siRNAs. Three 
independent experiments were performed. All error bars show s.e.m. *P < 0.05, **P < 0.01, and 
***P < 0.001. E. Proposed model for the regulation of HCC progression by CIC-ETV4-MMP1 
axis. 
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Figure 1. Decreased CIC protein levels in HCC cells and its correlation with poor survival rates in HCC 
patients. A. Analysis of TCGA database for expression levels of CIC mRNA in normal liver (NL) and HCC 
samples of four different clinicopathologic stages (I, II, III, and IV). The numbers in parentheses mean the 
number of subjects in each group. ***P < 0.001. B. Kaplan-Meier analysis of overall survival for HCC 
patients with high (the upper 20%) or low (the lower 20%) CIC expression (74 patients per each subgroup). 
*P < 0.05. C. Analysis of CIC protein levels in normal liver (n=33) and HCC (n=554) tissues using tissue 
microarrays. Immunohistochemical staining of CIC was conducted. Representative immunohistochemistry 
images showing four different expression levels of CIC in normal liver and HCC tissues were presented in the 
left panel. Scale bars indicate 100 µm. The right panel shows the proportion of tissue samples with different 
CIC expression scores. D. Western blot and qRT-PCR analyses of CIC expression profiles in normal liver (NL) 
and HCC samples.  
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Figure 2. CIC suppresses cell proliferation, migration, and invasion in HCC cells. A. Western blot analysis for 
ectopic expression of CIC-S and CIC-L in HCC cells (SK-HEP-1 and MHCC-97H). B. Cell growth assay of 
control and CIC-overexpressing HCC cells. C. Matrigel invasion assay of control and CIC-overexpressing HCC 
cells. The bottom panel is a bar graph for quantification of cell invasiveness. D. Transwell migration assay of 
control and CIC-overexpressing HCC cells. The bottom panel is a bar graph for quantification of cell 
migration. E. Western blot analysis showing knockdown efficiency of shCIC in HCC cells. shNC is for a 
negative control shRNA. F. Cell growth assay of control and shCIC-expressing HCC cells. G. Matrigel invasion 
assay of control and shCIC-expressing HCC cells. The right panel is a bar graph for quantification of cell 
invasiveness. H. Transwell migration assay of control and shCIC-expressing HCC cells. The right panel is a 
bar graph for quantification of cell migration. Three independent experiments were performed. All error bars 
show s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001.  
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Figure 3. CIC deficiency promotes tumor growth and metastasis in vivo. A. In vivo subcutaneous tumor 
growth curves of SK-HEP-1 and MHCC-97H cells with shNC- or shCIC-lentiviral infection. n=12 per each 
group. The middle panel is a representative image of xenograft tumors dissected from the mice after the last 
measurement of tumor size. The right panel is a graph for average weights of the dissected tumors. B. In 
vivo imaging of lung tissues into which intravenously-injected control or shCIC-expressing SK-HEP-1 and 
MHCC-97H cells metastasized. GFP signals expressed in the injected cells are shown as dot plots. The right 
panel is a bar graph for quantification of GFP signals. n=10 per each group. All error bars show s.e.m. *P < 
0.05 and **P < 0.01. C. A bar graph for the incidence (black area) of lung metastasis in each group of the 
nude mice.  
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Figure 4. Enhanced lung metastasis in liver-specific Cic null mice treated with DEN. A. Western blot images 
of CIC and β-actin (loading control) in liver and lung tissues of wild-type (WT) and liver-specific Cic null (Cic 
LKO) mice. B. Experimental scheme for analysis of tumorigenesis and lung metastasis of HCC in mice 
treated with diethylnitrosamine (DEN). C. Representative images of tumor-bearing livers from 8-month-old 
WT and Cic LKO mice treated with DEN. Arrows indicate tumor foci. The right panel is a bar graph for the 
average numbers of tumor foci on liver tissues of the DEN-treated WT and Cic LKO mice at 8 months of age. 
n=6 per each group. D. Representative images of H&E-stained lung tissues of DEN-treated WT and Cic LKO 
mice at 15 months of age. The right panel is a bar graph for the average numbers of tumor lesions in 
randomly selected lung tissue sections. Numbers of WT and Cic LKO mice used for this analysis are 10 and 
8, respectively. E. Kaplan–Meier survival curve of the DEN-treated WT (n=11) and Cic LKO mice (n=11). All 
error bars show s.e.m. *P < 0.05.  
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Figure 5. ETV4 is a major CIC target with the most significant relevance to HCC among PEA3 group genes. 
A. Analysis of TCGA database for expression levels of ETV1, ETV4, and ETV5 in normal liver (NL) and HCC 
samples of four different clinicopathologic stages (I, II, III, and IV). The numbers in parentheses mean the 
number of subjects in each group. B. Kaplan-Meier analysis of overall survival for HCC patients with high or 
low expression of PEA3 group genes (74 patients per each subgroup). C. qRT-PCR analysis of PEA3 group 
gene expression levels in control and CIC knockdown HCC cells. Experiments were performed more than 
three times, independently. D. Western blot analysis for levels of ETV4 in control and CIC knockdown HCC 
cells. E. qRT-PCR analysis for levels of Cic, Etv1, Etv4, and Etv5 in livers of 7-week-old WT and Cic LKO 
mice. n=6 per each genotype. F and G. qRT-PCR analysis for levels of Cic, Etv1, Etv4, and Etv5 in liver 
tumors harvested from the DEN-treated WT and Cic LKO mice at 8 months of age (F) and at 15 months of 
age (G). n=5 per each genotype. All error bars show s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001.  
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Figure 6. CIC deficiency-mediated promotion of HCC progression is due to derepression of ETV4. A. Western 
blot analysis showing ectopic expression of ETV4 in SK-HEP-1 and MHCC-97H cells. B-D. Cell growth assay 
(B), matrigel invasion assay (C), and transwell migration assay (D) of control and ETV4-overexpressing HCC 
cells. E. qRT-PCR analysis for ETV4 mRNA levels in control and CIC knockdown HCC cells transfected with 
either control or ETV4 siRNA. NN: control HCC cells transfected with control siRNA, N4: control HCC cells 
transfected with ETV4 siRNA (siETV4), CN: CIC knockdown HCC cells transfected with control siRNA, and C4: 
CIC knockdown HCC cells transfected with siETV4. F-H. Cell growth assay (F), matrigel invasion assay (G), 
and transwell migration assay (H) of control and CIC knockdown HCC cells treated with either control or 
ETV4 siRNA. Three independent experiments were performed. All error bars show s.e.m. *P < 0.05, **P < 
0.01, and ***P < 0.001.  
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Figure 7. MMP1 expression is regulated by the CIC-ETV4 axis. A. Analysis of TCGA database for expression 
levels of MMP1 in normal liver (NL) and HCC samples of four different clinicopathologic stages (I, II, III, and 
IV). The numbers in parentheses mean the number of subjects in each group. B. Kaplan-Meier analysis of 
overall survival for HCC patients with high or low MMP1 expression (74 patients per each subgroup). C. qRT-
PCR analysis for levels of MMP1, MMP10, and MMP12 in control and ETV4-overexpressing HCC cells (SK-HEP-
1 and MHCC-97H). D. Dual luciferase assay for regulation of MMP1 promoter activity by ETV4. The left panel 
is a schematic illustration for the luciferase reporter construct harboring MMP1 promoter region (-663/+1), 
in which there are two putative ETV4 binding sites (-323/-319 and -155/-149). The right panel is a bar 
graph for relative luciferase activity in the presence or absence of ETV4 overexpression. E. qRT-PCR analysis 
for levels of MMP1, MMP10, and MMP12 in control and CIC knockdown HCC cells. F. qRT-PCR analysis for 
MMP1 levels in control and CIC knockdown HCC cells treated with either control or ETV4 siRNA. NN: control 
HCC cells transfected with control siRNA, N4: control HCC cells transfected with siETV4, CN: CIC knockdown 
HCC cells transfected with control siRNA, and C4: CIC knockdown HCC cells transfected with siETV4. Three 
independent experiments were performed. All error bars show s.e.m. *P < 0.05, **P < 0.01, and ***P < 
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Figure 8. Upregulation of MMP1 expression contributes to the increased cell proliferation and invasion in CIC 
knockdown HCC cells. A. qRT-PCR analysis for MMP1 levels in control and CIC knockdown HCC cells treated 
with either control or MMP1 siRNAs. NN: control HCC cells transfected with control siRNA, N1-1: control HCC 
cells transfected with MMP1 siRNA-1 (siMMP1-1), N1-2: control HCC cells transfected with MMP1 siRNA-2 
(siMMP1-2), CN: CIC knockdown HCC cells transfected with control siRNA, C1-1: CIC knockdown HCC cells 
transfected with siMMP1-1, and C1-2: CIC knockdown HCC cells transfected with siMMP1-2. B-D. Cell 
proliferation assay (B), matrigel invasion assay (C), and transwell migration assay (D) of control and CIC 
knockdown HCC cells treated with either control or MMP1 siRNAs. Three independent experiments were 
performed. All error bars show s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001. E. Proposed model for the 
regulation of HCC progression by CIC-ETV4-MMP1 axis.  
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